Pharvaris NV reports results for the quarter ended December 31 - Earnings Summary

Pharvaris NV

08/04/2025 22:01

Pharvaris NV PHVS.OQ reported a quarterly adjusted loss of 64 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -76 cents.  The mean expectation of seven analysts for the quarter was for a loss of 72 cents per share. Wall Street expected results to range from -79 cents to -65 cents per share.

Reported revenue was zero​; analysts expected zero.

Pharvaris NV's reported EPS for the quarter was a loss of 64 cents​.

The company reported a quarterly loss of €34.76 million.

Pharvaris NV shares had fallen by 15.9% this quarter and lost 31.1% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts was unchanged in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Pharvaris NV is $32.00

This summary was machine generated from LSEG data April 8 at 09:00 p.m. UTC. ​All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.72
-0.64
Beat
Sep. 30 2024
-0.61
-0.77
Missed
Jun. 30 2024
-0.55
-0.55
Met
Mar. 31 2024
-0.56
-0.52
Beat